دورية أكاديمية
Use of Percutaneous Left Ventricular Assist Device Before Durable Device Implantation in Patients With Cardiac Cachexia: Case Series.
| العنوان: | Use of Percutaneous Left Ventricular Assist Device Before Durable Device Implantation in Patients With Cardiac Cachexia: Case Series. |
|---|---|
| المؤلفون: | Salas De Armas IA; From the Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Center at Houston, Houston, Texas., Bergeron A; Memorial Hermann Hospital-Texas Medical Center, Houston, Texas., Akkanti B; Divisions of Pulmonary, Critical Care, and Sleep, The University of Texas Health Science Center at Houston, Houston, Texas., Akay MH; From the Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Center at Houston, Houston, Texas., Scovell A; Memorial Hermann Hospital-Texas Medical Center, Houston, Texas., Patel MK; From the Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Center at Houston, Houston, Texas., Patel J; From the Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Center at Houston, Houston, Texas., Bhardwaj A; From the Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Center at Houston, Houston, Texas., Al Rameni D; From the Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Center at Houston, Houston, Texas., Marcano J; From the Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Center at Houston, Houston, Texas., Nascimbene A; From the Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Center at Houston, Houston, Texas., Kar B; From the Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Center at Houston, Houston, Texas., Gregoric ID; From the Department of Advanced Cardiopulmonary Therapies and Transplantation, The University of Texas Health Science Center at Houston, Houston, Texas. |
| المصدر: | ASAIO journal (American Society for Artificial Internal Organs : 1992) [ASAIO J] 2023 Jul 01; Vol. 69 (7), pp. e354-e359. Date of Electronic Publication: 2023 Apr 10. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9204109 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-943X (Electronic) Linking ISSN: 10582916 NLM ISO Abbreviation: ASAIO J Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Hagerstown, MD : Lippincott Williams & Wilkins Original Publication: Philadelphia, PA : Published for the Society by J.B. Lippincott Co., c1992- |
| مواضيع طبية MeSH: | Heart-Assist Devices* , Heart Failure*/complications , Heart Failure*/surgery, Humans ; Male ; Female ; Retrospective Studies ; Cachexia/etiology ; Treatment Outcome ; Shock, Cardiogenic |
| مستخلص: | Frailty and malnutrition in patients with heart failure are barriers to durable left ventricular assist device (D-LVAD) support and heart transplantation. Moreover, cachexia in patients with advanced heart failure carries a high mortality risk. There are no guidelines for these patients other than increased caloric intake and rehabilitation. Patients suffering from cardiac cachexia and heart failure may benefit from temporary, percutaneous assist device support to improve the underlying heart disease and reverse the catabolic state. We retrospectively reviewed patients from January 2017 to January 2022. All patients who received Impella support (5.0 or 5.5, Abiomed) before D-LVAD implantation were screened. Those who met the criteria for cardiac cachexia were included. Patient demographics, nutritional and biochemical markers, and survival data were collected. A total of 14 patients were included. The majority of patients were male (85.7%) with ischemic cardiomyopathy (64.3%). Caloric intake, physical strength, and ambulation improved. Prealbumin levels improved from a median of 13.7-18.0 mg/dl ( p < 0.006) while on Impella 5.0 or 5.5 support. All patients survived to discharge and the 6 month follow-up. In conclusion, use of the Impella device improves cardiogenic shock symptoms and, consequently, may improve cachexia status prior to D-LVAD implantation. (Copyright © ASAIO 2023.) |
| References: | Krysztofiak H, Wleklik M, Migaj J, et al.: Cardiac cachexia: A well-known but challenging complication of heart failure. Clin Interv Aging 15: 2041–2051, 2020. Hweidi IM, Al-Omari AK, Rababa MJ, Al-Obeisat SM, Hayajneh AA: Cardiac cachexia among patients with chronic heart failure: A systematic review. Nurs Forum 56: 916–924, 2021. Miller L, Birks E, Guglin M, Lamba H, Frazier OH: Use of ventricular assist devices and heart transplantation for advanced heart failure. Circ Res 124: 1658–1678, 2019. Vaid S, Bell T, Grim R, Ahuja V: Predicting risk of death in general surgery patients on the basis of preoperative variables using American College of Surgeons National Surgical Quality Improvement Program data. Perm J 16: 10–17, 2012. Evans WJ, Morley JE, Argilés J, et al.: Cachexia: A new definition. Clin Nutr 27: 793–799, 2008. Salas De Armas IA, Patel MK, Patel JA, et al.: Insertion of Impella 5.5 via the axillary artery graft under fluoroscopic guidance. Oper Tech Thorac Cardiovasc Surg 26: 462–474, 2021. McClave SA, Martindale RG, Vanek VW, et al.: Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). J Parenter Enter Nutr 33: 277–316, 2009. Go PH, Hodari A, Nemeh HW, et al.: Effect of preoperative albumin levels on outcomes in patients undergoing left ventricular device implantation. ASAIO J 61: 734–737, 2015. Guvenc TS, Güzelburc O, Ekmekci A, et al.: The effect of left ventricular assist device implantation on serum albumin, total protein and body mass: A short-term, longitudinal follow-up study. Hear Lung Circ 26: 702–708, 2017. Critsinelis AC, Kurihara C, Kawabori M, Sugiura T, Civitello AB, Morgan JA: Preoperative prealbumin level as a predictor of outcomes in patients who underwent left ventricular assist device implantation. Am J Cardiol 120: 1998–2002, 2017. Rodrigo ME, Majure DT, Sheikh FH, et al.: Prealbumin as a predictor of mortality after LVAD implantation. J Heart Lung Transplant 35: S339–S339, 2016. Critsinelis AC, Kurihara C, Kawabori M, et al.: Predictive value of preoperative serum albumin levels on outcomes in patients undergoing LVAD implantation. J Card Surg 33: 469–478, 2018. Keller U: Nutritional markers in malnutrition. J Clin Med 8: 775, 2019. Williams DGA, Molinger J, Wischmeyer PE: The malnourished surgery patient: A silent epidemic in perioperative outcomes? Curr Opin Anaesthesiol 32: 405–411, 2019. Muscaritoli M, Anker SD, Argilés J, et al.: Consensus definition of sarcopenia, cachexia and pre-cachexia: Joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics.” Clin Nutr 29: 154–159, 2010. Yoshioka D, Sakaguchi T, Saito S, et al.: Predictor of early mortality for severe heart failure patients with left ventricular assist device implantation: Significance of INTERMACS level and renal function. Circ J 76: 1631–1638, 2012. Lainscak M, Filippatos GS, Gheorghiade M, Fonarow GC, Anker SD: Cachexia: Common, deadly, with an urgent need for precise definition and new therapies. Am J Cardiol 101: 8E–10E, 2008. |
| تواريخ الأحداث: | Date Created: 20230411 Date Completed: 20230703 Latest Revision: 20231116 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1097/MAT.0000000000001902 |
| PMID: | 37039827 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1538-943X |
|---|---|
| DOI: | 10.1097/MAT.0000000000001902 |